Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Fineline Cube Jan 30, 2026
Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026
Company Drug

Jiangsu Suzhong Pharma’s Sutetinib Earns Breakthrough Designation for NSCLC from China’s NMPA

Fineline Cube Jul 25, 2024

Jiangsu Suzhong Pharma Group Co., Ltd, a leading pharmaceutical company based in China, has received...

Company Deals Medical Device

Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal

Fineline Cube Jul 25, 2024

China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc....

Company Deals

RemeGen Scales Back Private Placement to Fund New Drug R&D

Fineline Cube Jul 25, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan,...

Policy / Regulatory

China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program

Fineline Cube Jul 25, 2024

The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Cleared for Clinical Trial by NMPA

Fineline Cube Jul 25, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

Hinova Pharmaceuticals Receives NMPA Approval to Test Myelofibrosis Drug Candidate HP560

Fineline Cube Jul 25, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biopharmaceutical company based in Chengdu, has announced that it...

Company Drug

Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review

Fineline Cube Jul 25, 2024

Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...

Company Deals

Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million

Fineline Cube Jul 25, 2024

Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option...

Company Deals

Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies

Fineline Cube Jul 25, 2024

Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...

Company Drug

Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study

Fineline Cube Jul 25, 2024

Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...

Company Drug

Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults

Fineline Cube Jul 24, 2024

Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis

Fineline Cube Jul 24, 2024

China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...

Company Drug

ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China

Fineline Cube Jul 24, 2024

ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...

Company

Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities

Fineline Cube Jul 24, 2024

Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...

Company Medical Device

Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures

Fineline Cube Jul 24, 2024

Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...

Company Drug

Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China

Fineline Cube Jul 24, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...

Company

BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing

Fineline Cube Jul 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...

Company Drug

Bayer’s BAY 3375968 Receives NMPA Approval for Clinical Trial in Advanced Solid Tumors

Fineline Cube Jul 24, 2024

Bayer AG (ETR: BAYN), a multinational pharmaceutical giant based in Germany, has received clinical trial...

Company Drug

Chipscreen’s HDAC Inhibitor Chidamide to be Tested in Combination Therapy for CRC by NMPA

Fineline Cube Jul 24, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a biopharmaceutical company based in China, has received...

Company Deals

Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328

Fineline Cube Jul 24, 2024

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...

Posts pagination

1 … 275 276 277 … 616

Recent updates

  • Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611
  • Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials
  • Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21
  • CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio
  • Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Company Drug

Hengrui Cancer Combo Gets NMPA Nod for Liver Cancer Trials

Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.